Health and Healthcare

Parnell Pharma Soars on Business Update

Chris Lange

Published: April 22, 2016 12:50 pm

Last Updated: January 13, 2020 10:25 am

Parnell Pharmaceuticals Holding Ltd. (NASDAQ: PARN) saw its shares take a sharp uptick into the weekend following a solid business update. The company announced business results for the first quarter of 2016 that included strong revenue growth of 43%, the conclusion of negotiations on a contract manufacturing agreement with a major multinational, the upcoming launch of two new products — Luminous and Reviderm —and receipt of the U.S. Food and Drug Administration (FDA) response for the two remaining Technical Sections for Zydax for dogs in the United States.

During this quarter, Parnell’s sales growth totaled 43% for the first quarter, over the same period in 2015. Sales grew 10% from last year in the U.S. Production Animal segment, while the sales growth was 83% for the Rest-of-the-World Animal segment.

The company received the FDA’s response to its filings of the Target Animal Effectiveness Technical Section and the Chemistry and Manufacturing Controls Technical Section for Zydax. Parnell expects that adequate responses to the FDA can be prepared and filed by the second quarter, and that a potential approval could be expected by late in the fourth quarter.

Parnell completed its in-licensing of Reviderm in this quarter. Reviderm is a novel antimicrobial liquid bandage for the treatment of wounds on dogs, cats and horses.

24/7 Wall St.
10 Great Stocks That Warren Buffett Should Have Never Sold